Systemic corticosteroid treatment and risk of infectious diseases;Corticothérapie systémique et risque infectieux

Revue de Medecine Interne

Volumn 28, Issue 12, 2007, Pages 841-851

  Dussauze, H ^a   Bourgault, I ^a   Doleris, L M ^a   Prinseau, J ^a   Baglin, A ^a   Hanslik, T ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Adverse event; Corticosteroid; Immunosuppression; Infection; Prednisone

Indexed keywords

ACICLOVIR; ALBENDAZOLE; ANTIVIRUS AGENT; CHICKENPOX VACCINE; CORTICOSTEROID; COTRIMOXAZOLE; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN; IVERMECTIN; LAMIVUDINE; PREDNISONE; RIFAMPICIN; STREPTOCOCCUS VACCINE; VALACICLOVIR;

APOPTOSIS; CD4+ T LYMPHOCYTE; CHICKENPOX; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUSHING SYNDROME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG METABOLISM; HEPATITIS B; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INCIDENCE; INFECTION; INFLAMMATION; META ANALYSIS; PNEUMOCYSTOSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SHORT SURVEY; STREPTOCOCCUS INFECTION; STRONGYLOIDIASIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; CUSHING SYNDROME; EOSINOPHILS; HEPADNAVIRIDAE INFECTIONS; HUMANS; IMMUNE SYSTEM; INFECTION; INFLAMMATION; MACROPHAGES; MONOCYTES; NEUTROPHILS; RISK ASSESSMENT; RISK FACTORS;

EID: 36249026222     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.05.030     Document Type: Short Survey

References (110)

1. Hench P.S., Kendall E.C., Slocumb C.H., and Polley H.F. Effects of cortisone acetate and pituitary acth on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch. Med. Interna 85 (1950) 545-666
2. Fauci A.S., Dale D.C., and Balow J.E. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann. Intern. Med. 84 (1976) 304-315
3. Gluck T., Kiefmann B., Grohmann M., Falk W., Straub R.H., and Scholmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J. Rheumatol. 32 (2005) 1473-1480
4. Oehling A.G., Akdis C.A., Schapowal A., Blaser K., Schmitz M., and Simon H.U. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 52 (1997) 144-154
5. Fauci A.S. Mechanisms of the immunosuppressive and anti-inflammatory effects of glucocorticosteroids. J. Immunopharmacol. 1 (1978) 1-25
6. Bakker R.C., Gallas P.R., Romijn J.A., and Wiersinga W.M. Cushing's syndrome complicated by multiple opportunistic infections. J. Endocrinol. Invest. 21 (1998) 329-333
7. Heinbecker P., and Pfeiffenberger Jr. M. Further clinical and experimental studies on the pathogenesis of cushing's syndrome. Am. J. Med. 9 (1950) 3-23
8. Plotz C.M., Knowlton A.I., and Ragan C. The natural history of cushing's syndrome. Am. J. Med. 13 (1952) 597-614
9. Klein N.C., Go C.H., and Cunha B.A. Infections associated with steroid use. Infect. Dis. Clin. North Am. 15 (2001) 423-432 (viii)
10. Kang I., and Park S.H. Infectious complications in sle after immunosuppressive therapies. Curr. Opin. Rheumatol. 15 (2003) 528-534
11. Hellmann D.B., Petri M., and Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66 (1987) 341-348
12. Moreland L.W., and O'Dell J.R. Glucocorticoids and rheumatoid arthritis: back to the future?. Arthritis Rheum. 46 (2002) 2553-2563
13. Segal B.H., and Sneller M.C. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum. Dis. Clin. North Am. 23 (1997) 219-237
14. Lepper M.H. Prophylaxis in patients receiving adrenal steroid therapy. J. Chronic Dis. 15 (1962) 691-711
15. Mukwaya G. Immunosuppressive effects and infections associated with corticosteroid therapy. Pediatr. Infect. Dis. J. 7 (1988) 499-504
16. Drouhet E., and Dupont B. Infections fungiques et parasitaires lors des traitements immunosuppresseurs. Pathol. Biol. (Paris) 24 (1976) 99-116
17. Balow J.E., Hurley D.L., and Fauci A.S. Immunosuppressive effects of glucocorticosteroids: differential effects of acute versus chronic administration on cell-mediated immunity. J. Immunol. 114 (1975) 1072-1076
18. Kleinert H., Euchenhofer C., Ihrig-Biedert I., and Forstermann U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa b. Mol. Pharmacol. 49 (1996) 15-21
19. Kovalovsky D., Refojo D., Holsboer F., and Arzt E. Molecular mechanisms and th1/th2 pathways in corticosteroid regulation of cytokine production. J. Neuroimmunol. 109 (2000) 23-29
20. + T cells in vitro. J. Immunol. 156 (1996) 2406-2412
21. Marx J. How the glucocorticoids suppress immunity. Science 270 (1995) 232-233
22. Lebrun-Vignes B. Corticothérapie et immunologie. In: Papo T. (Ed). Immunologie (2001), Doin, Paris 433-443
23. Shoenfeld Y., Gurewich Y., Gallant L.A., and Pinkhas J. Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis. Am. J. Med. 71 (1981) 773-778
24. Goulding N.J., Euzger H.S., Butt S.K., and Perretti M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm. Res. 47 Suppl 3 (1998) S158-S165
25. Dunsky E.H., Zweiman B., Fischler E., and Levy D.A. Early effects of corticosteroids on basophils, leukocyte histamine, and tissue histamine. J. Allergy Clin. Immunol. 63 (1979) 426-432
26. Garber E.K., Fan T.F., and Bluestone R. Realistic guidelines of corticosteroid therapy in rheumatic disease. Semin. Arthritis Rheum. 11 (1981) 231-253
27. Lionakis M.S., and Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet 362 (2003) 1828-1838
28. Porges A.J., Beattie S.L., Ritchlin C., Kimberly R.P., and Christian C.L. Patients with systemic lupus erythematosus at risk for pneumocystis carinii pneumonia. J. Rheumatol. 19 (1992) 1191-1194
29. Kadoya A., Okada J., Iikuni Y., and Kondo H. Risk factors for pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J. Rheumatol. 23 (1996) 1186-1188
30. Godeau B., Coutant-Perronne V., Le Thi Huong D., Guillevin L., Magadur G., De Bandt M., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J. Rheumatol. 21 (1994) 246-251
31. Gluck T., Geerdes-Fenge H.F., Straub R.H., Raffenberg M., Lang B., Lode H., et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 28 (2000) 227-230
32. Li J., Huang X.M., Fang W.G., and Zeng X.J. Pneumocystis carinii pneumonia in patients with connective tissue disease. J. Clin Rheumatol. 12 (2006) 114-117
33. Sowden E., and Carmichael A.J. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect. Dis. 4 (2004) 42
34. + T-lymphocyte counts during pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118 (2000) 712-720
35. Aucott J.N. Glucocorticoids and infection. Endocrinol. Metab. Clin. North Am. 23 (1994) 655-670
36. Boumpas D.T., Chrousos G.P., Wilder R.L., Cupps T.R., and Balow J.E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119 (1993) 1198-1208
37. Butler W.T. Corticosteroids and immunoglobulin synthesis. Transplant. Proc. 7 (1975) 49-53
38. Lee R.J., and Fay A.C. Hypogammaglobulinaemia associated with long-term, low-dose steroid therapy. Postgrad. Med. J. 61 (1985) 523-524
39. Posey W.C., Nelson H.S., Branch B., and Pearlman D.S. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J. Allergy Clin. Immunol. 62 (1978) 340-348
40. Kawano T., Matsuse H., Obase Y., Kondo Y., Machida I., Tomari S., et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int. Arch. Allergy Immunol. 128 (2002) 240-243
41. Klaustermeyer W.B., Gianos M.E., Kurohara M.L., Dao H.T., and Heiner D.C. IgG subclass deficiency associated with corticosteroids in obstructive lung disease. Chest 102 (1992) 1137-1142
42. Lack G., Ochs H.D., and Gelfand E.W. Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. J. Pediatr. 129 (1996) 898-903
43. Stuck A.E., Minder C.E., and Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev. Infect. Dis. 11 (1989) 954-963
44. Bovornkitti S., Kangsadal P., Sathirapat P., and Oonsombatti P. Reversion and reconversion rate of tuberculin skin reactions in correction with the use of prednisone. Dis. Chest 38 (1960) 51-55
45. Kim H.A., Yoo C.D., Baek H.J., Lee E.B., Ahn C., Han J.S., et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin. Exp. Rheumatol. 16 (1998) 9-13
46. West B.C., and Wilson J.P. Subconjunctival corticosteroid therapy complicated by hyperinfective strongyloidiasis. Am. J. Ophthalmol. 89 (1980) 854-857
47. Guven A., Karadeniz S., Aydin O., Akbalik M., and Aydin M. Fatal disseminated cytomegalovirus infection in an infant with cushing's syndrome caused by topical steroid. Horm. Res. 64 (2005) 35-38
48. Dale D.C., Fauci A.S., Guerry D.I., and Wolff S.M. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J. Clin. Invest. 56 (1975) 808-813
49. MacGregor R.R., Sheagren J.N., Lipsett M.B., and Wolff S.M. Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N. Engl. J. Med. 280 (1969) 1427-1431
50. Fauci A.S. Alternate-day corticosteroid therapy. Am. J. Med. 64 (1978) 729-731
51. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 46 (2002) 2294-2300
52. Sarlis N.J., Chanock S.J., and Nieman L.K. Cortisolemic indices predict severe infections in cushing syndrome due to ectopic production of adrenocorticotropin. J. Clin. Endocrinol. Metab. 85 (2000) 42-47
53. Graham B.S., and Tucker Jr. W.S. Opportunistic infections in endogenous cushing's syndrome. Ann. Intern. Med. 101 (1984) 334-338
54. Roblot F., Le Moal G., Godet C., Hutin P., Texereau M., Boyer E., et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: A descriptive study. J. Infect. 47 (2003) 19-27
55. Chatham W.W., and Kimberly R.P. Treatment of lupus with corticosteroids. Lupus 10 (2001) 140-147
56. Noel V., Lortholary O., Casassus P., Cohen P., Genereau T., Andre M.H., et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann. Rheum. Dis. 60 (2001) 1141-1144
57. Frey F.J. Kinetics and dynamics of prednisolone. Endocr. Rev. 8 (1987) 453-473
58. Gustavson L.E., Legler U.F., and Benet L.Z. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J. Clin. Endocrinol. Metab. 62 (1986) 234-237
59. Stanbury R.M., and Graham E.M. Systemic corticosteroid therapy-side effects and their management. Br. J. Ophthalmol. 82 (1998) 704-708
60. Wiest P.M., Flanigan T., Salata R.A., Shlaes D.M., Katzman M., and Lederman M.M. Serious infectious complications of corticosteroid therapy for copd. Chest 95 (1989) 1180-1184
61. Bateman E.D. Is tuberculosis chemoprophylaxis necessary for patients receiving corticosteroids for respiratory disease?. Respir. Med. 87 (1993) 485-487
62. Cline J.C., and Davis S.M. Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Ann. Pharmacother. 31 (1997) 775-776
63. Agrawal P.N., Gupta D., Aggarwal A.N., and Behera D. Incidence of tuberculosis among patients receiving treatment with oral corticosteroids. J. Assoc. Physicians India 48 (2000) 881-884
64. American thoracic society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. Rep. 49 (2000) 1-51
65. Jick S.S., Lieberman E.S., Rahman M.U., and Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 55 (2006) 19-26
66. Senderovitz T., and Viskum K. Corticosteroids and tuberculosis. Respir. Med. 88 (1994) 561-565
67. Schatz M., Patterson R., Kloner R., and Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann. Intern. Med. 84 (1976) 261-265
68. Kobashi Y., and Matsushima T. Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy. Intern. Med. 41 (2002) 1103-1110
69. Heym B., and Chinet T. Méthodes diagnostiques de l'infection tuberculeuse en 2007 : intradermoréaction à la tuberculine ou interféron-gamma ?. Rev. Med. Interne 28 (2007) 147-150
70. Pai M., and Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?. Clin. Infect. Dis. 44 (2007) 74-77
71. Pai M., and Menzies D. The new igra and the old tst: making good use of disagreement. Am. J. Respir. Crit. Care Med. 175 (2007) 529-531
72. Hill G., Chauvenet A.R., Lovato J., and McLean T.W. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics 116 (2005) e525-e529
73. Dowell S.F., and Bresee J.S. Severe varicella associated with steroid use. Pediatrics 92 (1993) 223-228
74. Patel H., Macarthur C., and Johnson D. Recent corticosteroid use and the risk of complicated varicella in otherwise immunocompetent children. Arch. Pediatr. Adolesc. Med. 150 (1996) 409-414
75. Goldstein S.L., Somers M.J., Lande M.B., Brewer E.D., and Jabs K.L. Aciclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr. Nephrol. 14 (2000) 305-308
76. Reiches N.A., and Jones J.F. Steroids and varicella. Pediatrics 92 (1993) 288-289
77. Prober C.G. Aciclovir therapy in a steroid recipient with varicella. Pediatr. Infect. Dis. J. 16 (1997) 1095-1096
78. Schaffner W. Varicella vaccination for adolescents with asthma. Pediatr. Infect. Dis. J. 16 (1997) 723
79. Vento S., Cainelli F., and Longhi M.S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 3 (2002) 333-340
80. Magy N., Cribier B., Schmitt C., Ellero B., Jaeck D., Boudjema K., et al. Effects of corticosteroids on hcv infection. Int. J. Immunopharmacol. 21 (1999) 253-261
81. Vassiliadis T., Garipidou V., Tziomalos K., Perifanis V., Giouleme O., and Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: a prospective case series. Am. J. Hematol. 80 (2005) 197-203
82. Shibolet O., Ilan Y., Gillis S., Hubert A., Shouval D., and Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100 (2002) 391-396
83. Sepkowitz K.A., Brown A.E., Telzak E.E., Gottlieb S., and Armstrong D. Pneumocystis carinii pneumonia among patients without aids at a cancer hospital. JAMA 267 (1992) 832-837
84. Sepkowitz K.A. Pneumocystis carinii pneumonia in patients without aids. Clin. Infect. Dis. 17 Suppl 2 (1993) S416-S422
85. Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis. 34 (2002) 1098-1107
86. Castro M. Treatment and prophylaxis of pneumocystis carinii pneumonia. Semin. Respir. Infect. 13 (1998) 296-303
87. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 33 (2001) 139-144
88. Beck J.M., and Harmsen A.G. Lymphocytes in host defense against pneumocystis carinii. Semin. Respir. Infect. 13 (1998) 330-338
89. Stankovic K., Seve P., Hot A., Magy N., Durieu I., and Broussolle C. Aspergilloses au cours de maladies systémiques traitées par corticoïdes et/ou immunosuppressuers : analyse de neuf cas et revue de la littérature. Rev. Med. Interne 27 (2006) 813-827
90. Dromer F., Mathoulin S., Dupont B., and Laporte A. Epidemiology of cryptococcosis in france: a 9-year survey (1985-1993). French cryptococcosis study group. Clin. Infect. Dis. 23 (1996) 82-90
91. Igra-Siegman Y., Kapila R., Sen P., Kaminski Z.C., and Louria D.B. Syndrome of hyperinfection with strongyloides stercoralis. Rev. Infect. Dis. 3 (1981) 397-407
92. Davidson R.A., Fletcher R.H., and Chapman L.E. Risk factors for strongyloidiasis. A case-control study. Arch. Intern. Med. 144 (1984) 321-324
93. Nucci M., Portugal R., Pulcheri W., Spector N., Ferreira S.B., de Castro M.B., et al. Strongyloidiasis in patients with hematologic malignancies. Clin. Infect. Dis. 21 (1995) 675-677
94. Gann P.H., Neva F.A., and Gam A.A. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J. Infect. Dis. 169 (1994) 1076-1079
95. Datry A., Hilmarsdottir I., Mayorga-Sagastume R., Lyagoubi M., Gaxotte P., Biligui S., et al. Treatment of strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans. R. Soc. Trop. Med. Hyg. 88 (1994) 344-345
96. Marti H., Haji H.J., Savioli L., Chwaya H.M., Mgeni A.F., Ameir J.S., et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of strongyloides stercoralis and other soil-transmitted helminth infections in children. Am. J. Trop. Med. Hyg. 55 (1996) 477-481
97. Conseil supérieur d'hygiène publique de France. Calendrier vaccinal 2006. BEH (2006) 29-30
98. Gluck T. Vaccinate your immunocompromised patients!. Rheumatology (Oxford) 45 (2006) 9-10
99. Kubiet M.A., Gonzalez-Rothi R.J., Cottey R., and Bender B.S. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest 110 (1996) 367-370
100. Steentoft J., Konradsen H.B., Hilskov J., Gislason G., and Andersen J.R. Response to pneumococcal vaccine in chronic obstructive lung disease: the effect of ongoing, systemic steroid treatment. Vaccine 24 (2006) 1408-1412
101. de Roux A., Schmidt N., Rose M., Zielen S., Pletz M., and Lode H. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir. Med. 98 (2004) 1187-1194
102. Andrieu J.M., and Lu W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med. 2 (2004) 17
103. + T lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis and therapy. AIDS 9 (1995) 35-42
104. Ulmer A., Muller M., Bertisch-Mollenhoff B., and Frietsch B. Low-dose prednisolone has a CD4-stabilizing effect in pre-treated HIV-patients during structured therapy interruptions. Eur. J. Med. Res. 10 (2005) 227-232
105. + T cell loss in therapy-naive HIV-patients without antiretroviral therapy. Eur. J. Med. Res. 10 (2005) 105-109
106. Wallis R.S., Kalayjian R., Jacobson J.M., Fox L., Purdue L., Shikuma C.M., et al. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J. Acquir. Immune Defic. Syndr. 32 (2003) 281-286
107. Miller K.D., Masur H., Jones E.C., Joe G.O., Rick M.E., Kelly G.G., et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann. Intern. Med. 137 (2002) 17-25
108. Salisbury D.M. Varicella. Immunisation against infectious disease. HMSO (1996) 251-261
109. Nishioka S.A. Corticosteroids and risk of complicated varicella. Arch. Pediatr. Adolesc. Med. 150 (1996) 1314
110. Rice P., Simmons K., Carr R., and Banatvala J. Near fatal chickenpox during prednisolone treatment. BMJ 309 (1994) 1069-1070